Estradiol cypionate/medroxyprogesterone acetate
pharmaceutical combination
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control. It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin. It is recommended for short-term use and is given once a month by injection into a muscle.
Common side effects of EC/MPA include irregular menstrual periods which typically improves with time. Other side effects include blood clots, headache, hair loss, depression, nausea, and breast pain. Use during pregnancy is not recommended. Use during breastfeeding is likely safe. It works mainly by preventing ovulation.
EC/MPA came into medical use in 1993 with approval in the United States in 2000. It is on the World Health Organization's List of Essential Medicines.
The public source identifies “Estradiol cypionate/medroxyprogesterone acetate” as pharmaceutical combination. This brief keeps that definition visible, then builds a research path around Estradiol, cypionate and medroxyprogesterone.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Estradiol cypionate/medroxyprogesterone acetate”, the useful work is to connect “pharmaceutical combination” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 21, 2026. The linked authority identifier is Q28163615. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1993 and 2000.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Estradiol cypionate/medroxyprogesterone acetate”, its source revision and the description used here.
- Expand the search: follow Estradiol cypionate/medroxyprogesterone acetate primary sources, Estradiol cypionate/medroxyprogesterone acetate archive and Estradiol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Estradiol cypionate/medroxyprogesterone acetate”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Estradiol cypionate/medroxyprogesterone acetate” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.